Mainz

• Phase 2 Study of REGN13335 in Adult Participants with Pulmonary Arterial Hypertension (PAH) Recruiting
  2024-514754-79-00 4 2026-05-06 Pulmonary Arterial Hypertension (PAH)
• A study to assess the effects of zigakibart on IgA nephropathy. Recruiting
  2024-519699-24-00 4 2026-04-23 IgA nephropathy
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive … Recruiting
  2024-514006-31-00 9 2026-04-16 Non-active Progressive Multiple Sclerosis (PMS)
• A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting
  2025-521521-33-00 10 2026-04-02 Kidney transplant rejection
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High R … Recruiting
  2025-523037-25-00 4 2026-03-10 Patients at high risk for Cardiac Surgery Associated – Acute Kidney In
• A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung can … Recruiting
  2025-522437-65-00 4 2026-03-06 small-cell lung cancer
• Essentiale® liquid once-daily Phase III study Recruiting
  2025-521678-32-00 5 2026-03-03 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MAS
• A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid art … Recruiting
  2025-522273-10-00 3 2026-02-24 Rheumatoid Arthritis
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 5 2025-12-16 Autosomal dominant polycystic kidney disease (ADPKD)
• SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting
  2025-520794-39-00 5 2025-12-10 Arterial Hypertension
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting
  2025-521293-34-00 4 2025-12-09 Moderate-to-severe hidradenitis suppurativa
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 4 2025-11-25 Mantle Cell Lymphoma (MCL)
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm … Recruiting
  2025-521268-37-00 6 2025-11-25 Respiratory tract diseases
• An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi … Recruiting
  2024-512714-18-00 9 2025-11-11 Relapsing Multiple Sclerosis
• A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers … Recruiting
  2025-521658-40-00 1 2025-10-27 Atopic dermatitis
• A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid a … Recruiting
  2024-520196-27-00 3 2025-10-01 Rheumatoid Arthritis

Showing 49–72 of 603 trials